

Supplemental Table. PSK significantly increased the trastuzumab-dependent lysis of breast cancer cells by human PBMC.

Donor	E:T Ratio	Percent Specific Lysis			
		SKBR3		MDA-MB-231	
		Trastuzumab	Trastuzumab+PSK	Trastuzumab	Trastuzumab+PSK
1	100:1	71.4%	95.6%	10.4%	12.8%
	50:1	47.0%	65.8%	6.2%	6.1%
	25:1	33.9%	42.1%	4.4%	4.5%
	12.5:1	14.8%	38.7%	2.7%	2.8%
2	100:1	72.9%	88.7%	11.7%	13.1%
	50:1	48.4%	77.2%	4.7%	10.3%
	25:1	31.6%	52.5%	2.7%	7.9%
	12.5:1	19.9%	42.6%	-1.2%	2.8%
3	100:1	75.1%	101.7%	40.0%	58.9%
	50:1	67.7%	83.0%	25.0%	39.3%
	25:1	52.8%	58.7%	18.4%	26.8%
	12.5:1	31.1%	49.6%	5.3%	16.8%
4	100:1	67.3%	86.0%	14.6%	30.9%
	50:1	50.0%	65.0%	7.3%	21.5%
	25:1	30.3%	51.7%	6.5%	11.1%
	12.5:1	16.0%	36.7%	5.1%	2.6%
5	100:1	7.2%	19.7%	4.6%	10.0%
	50:1	0.1%	12.9%	3.6%	6.2%
	25:1	0.1%	10.2%	1.1%	1.8%
	12.5:1	1.2%	2.4%	0.6%	-1.9%
Mean ±sem	100:1	58.8±12.9%	78.3±14.9%***	16.3±6.3%	25.1±9.2%*
	50:1	42.6±11.3%	60.8±12.5%**	9.4±3.9%	16.7±6.3%*
	25:1	29.7±8.5%	43.0±8.6%**	6.6±3.1%	10.4±4.4%*
	12.5:1	16.6±4.8%	34.0±8.2%*	2.5±1.3%	4.6±3.2%

*, $p < 0.05$, **, $p < 0.01$, ***, $p < 0.001$ between PBMC pretreated with PSK or no PSK by paired Student's *t* test.